Univariate prognostic analyses of polymorphisms
| Polymorphisms . | No. of patients . | Overall survival . | Freedom from progression . | Freedom from treatment failure . | |||
|---|---|---|---|---|---|---|---|
| Relative risk (95% CI) . | P . | Relative risk (95% CI) . | P . | Relative risk (95% CI) . | P . | ||
| UGT1A1: TA6/TA6 vs 67 and 77 | 309 (148 vs 130 and 31) | 1.68 (0.79-3.6) | .18 | 2.11 (1.15-3.89) | .014 | 1.86 (1.07-3.26) | .027 |
| CYP3A4: AA vs AG and GG | 310 (278 vs 29 and 3) | 0.68 (0.24-1.97) | .48 | 0.77 (0.33-1.81) | .55 | 0.76 (0.34-1.68) | .49 |
| GSTPIE5: AA vs AG and GG | 311 (130 vs 141 and 40) | 0.79 (0.45-1.39) | .41 | 1.02 (0.67-1.55) | .92 | 0.94 (0.63-1.4) | .76 |
| GSTT1 0 vs 1 | 312 (48 vs 264) | 0.43 (0.19-0.97) | .042 | 0.83 (0.39-1.78) | .63 | 0.75 (0.38-1.49) | .41 |
| GSTM1 0 vs 1 | 312 (164 vs 148) | 1.13 (0.54-2.36) | .75 | 1.52 (0.85-2.73) | .16 | 1.31 (0.76-2.25) | .32 |
| Polymorphisms . | No. of patients . | Overall survival . | Freedom from progression . | Freedom from treatment failure . | |||
|---|---|---|---|---|---|---|---|
| Relative risk (95% CI) . | P . | Relative risk (95% CI) . | P . | Relative risk (95% CI) . | P . | ||
| UGT1A1: TA6/TA6 vs 67 and 77 | 309 (148 vs 130 and 31) | 1.68 (0.79-3.6) | .18 | 2.11 (1.15-3.89) | .014 | 1.86 (1.07-3.26) | .027 |
| CYP3A4: AA vs AG and GG | 310 (278 vs 29 and 3) | 0.68 (0.24-1.97) | .48 | 0.77 (0.33-1.81) | .55 | 0.76 (0.34-1.68) | .49 |
| GSTPIE5: AA vs AG and GG | 311 (130 vs 141 and 40) | 0.79 (0.45-1.39) | .41 | 1.02 (0.67-1.55) | .92 | 0.94 (0.63-1.4) | .76 |
| GSTT1 0 vs 1 | 312 (48 vs 264) | 0.43 (0.19-0.97) | .042 | 0.83 (0.39-1.78) | .63 | 0.75 (0.38-1.49) | .41 |
| GSTM1 0 vs 1 | 312 (164 vs 148) | 1.13 (0.54-2.36) | .75 | 1.52 (0.85-2.73) | .16 | 1.31 (0.76-2.25) | .32 |
Relative risks and their 95% confidence intervals and P values were estimated for the 5 polymorphisms tested. Each line corresponds to the comparison of patients with the specified characteristic to the other patients. For GSTT1 and GSTM1, genotype is not available; the information 0 or 1 refers to the presence or absence of gene expression. Patients with rare or missing phenotypes are not included: 2 patients with alleles 5 and 2 with missing data for UGT1A, 3 patients with missing data for CYP3A4, and 2 patients with missing data for GSTP1.